gefitinib has been researched along with sulforaphane in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (sulforaphane) | Trials (sulforaphane) | Recent Studies (post-2010) (sulforaphane) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,754 | 65 | 1,317 |
| Protein | Taxonomy | gefitinib (IC50) | sulforaphane (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 9 | |
| Macrophage migration inhibitory factor | Homo sapiens (human) | 2.2 | |
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | 0.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, X; Jiang, H; Meng, J; Meng, W; Wang, K; Zhang, F; Zhao, F | 1 |
1 other study(ies) available for gefitinib and sulforaphane
| Article | Year |
|---|---|
Sulforaphane overcomes T790M-mediated gefitinib resistance in vitro through epithelial-mesenchymal transition.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Isothiocyanates; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Sulfoxides | 2021 |